Compare PVH & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PVH | TMDX |
|---|---|---|
| Founded | 1881 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.4B |
| IPO Year | 1994 | 2019 |
| Metric | PVH | TMDX |
|---|---|---|
| Price | $92.89 | $114.24 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 16 | 9 |
| Target Price | $90.53 | ★ $148.22 |
| AVG Volume (30 Days) | ★ 1.4M | 814.2K |
| Earning Date | 06-03-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.15% | N/A |
| EPS Growth | N/A | ★ 382.18 |
| EPS | 0.52 | ★ 4.87 |
| Revenue | ★ $8,950,200,000.00 | $605,494,000.00 |
| Revenue This Year | $1.89 | $24.25 |
| Revenue Next Year | $1.86 | $18.75 |
| P/E Ratio | $189.90 | ★ $22.40 |
| Revenue Growth | 3.44 | ★ 37.13 |
| 52 Week Low | $59.60 | $88.50 |
| 52 Week High | $100.00 | $156.00 |
| Indicator | PVH | TMDX |
|---|---|---|
| Relative Strength Index (RSI) | 68.05 | 50.88 |
| Support Level | $73.26 | $109.38 |
| Resistance Level | N/A | $131.86 |
| Average True Range (ATR) | 4.05 | 5.30 |
| MACD | 0.97 | 1.52 |
| Stochastic Oscillator | 75.01 | 73.21 |
PVH designs and markets branded apparel in more than 40 countries. Its key fashion categories include men's dress shirts, ties, sportswear, underwear, and jeans. Its two designer brands, Calvin Klein and Tommy Hilfiger, now generate practically all its revenue after its recent disposition of most of its smaller brands. PVH operates e-commerce sites, roughly 1,400 standalone stores, and about 1,500 shop-in-shops and concessions. The firm also licenses its brands to third parties and distributes its merchandise through department stores and other wholesale accounts. PVH traces its history to 1881 and is based in New York City.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.